Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

Phase 2UnknownNCT00002099

AJI Pharma USA

Overview

To determine the tolerance and side effects of a combination of lentinan and didanosine (ddI) in comparison with ddI alone. To determine whether the combination of lentinan and ddI produces a significant immunorestorative effect within the study observation period (6-12 months) as measured by an increase in one or more of the following: neutrophil count and activity, T-cell subsets, and a decrease in p24 antigen.

Patients are treated with daily oral ddI for 6 weeks, then are randomized to ddI in combination with intravenous lentinan or placebo (administered once weekly) for 26 weeks. Patients who are already stabilized on 400 mg/day ddI will proceed directly to randomization. Following completion of the combination therapy, patients may be offered 26 additional weeks of therapy on an optional basis.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

HIV Infections

Interventions

LentinanDRUG

DidanosineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria Patients must have: * HIV seropositivity. * Absolute CD4 count of 200 - 500 cells/mm3. * No active opportunistic infection or Kaposi's sarcoma. Prior Medication: Allowed: * Prior ddI for no longer than 3 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Lymphoid malignancy. * Pancreatitis. * Peripheral neuropathy. * Critical illness. Concurrent Medication: Excluded: * Antiretroviral agents other than ddI. * Steroids. * Cytotoxic agents. * Immunosuppressive agents. * Immunomodulators. * 1-Thyroxine. Concurrent Treatment: Excluded: * Radiotherapy. Prior Medication: Excluded within 1 month prior to study entry: * Antiretroviral agents other than ddI (patients may have received prior ddI for no longer than 3 months total). * Steroids. * Cytotoxic agents. * Immunosuppressive agents. * Immunomodulators. Prior Treatment: Excluded: * Radiotherapy within 1 month prior to study entry. Active IV drug abuse.

Locations (1)

HIV Research Group

San Diego, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.